Education
About Us
Working with TipRanks
Follow Us
Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$206.24M
Enterprise ValueAU$150.60M
Total Cash (Recent Filing)AU$1.96M
Total Debt (Recent Filing)AU$6.99M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Feb 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding793,213,700
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue ModelA two-pronged model (product sales plus contract/service and milestone revenue) provides durable revenue optionality. Product consumables can create recurring sales while development and manufacturing contracts deliver milestone and service fees, smoothing revenue timing and leveraging internal capabilities over multiple years.
High Gross MarginsA ~63% gross margin is a structural advantage in diagnostics: it supports operating leverage as volumes scale and provides scope to invest in R&D and manufacturing capacity. Sustained product-level margins improve long-term unit economics even if top-line growth is variable.
Clear Operational Targets And Capacity InvestmentManagement has set explicit medium-term targets (revenue growth and a 15% operating margin) and is investing in capacity. That strategic commitment to scale production and margin improvement, if executed, addresses structural constraints and can unlock durable profitability improvements.
Bears Say
Recent Revenue DeclineA material revenue decline shrinks the base needed to absorb fixed costs and capital investments. Persistent top-line contraction undermines scale economics, makes margin targets harder to reach, and heightens dependency on successful commercialization of products or partner programs to restore growth.
Negative Operating And Free Cash FlowOngoing operational cash burn is a durable constraint: it limits reinvestment capacity, forces reliance on external financing or equity raises, and increases execution risk for scaling manufacturing and commercialization. Weak cash generation can magnify business-cycle stress.
High Leverage And Negative ROEElevated leverage with negative ROE signals capital inefficiency and raises solvency risk. Debt servicing constraints limit financial flexibility for R&D, commercial expansion, or absorbing shocks. Structurally, this increases the probability of dilution or costly refinancing if cash flows don't improve.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.02 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$206.24M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Feb 23, 2026 which is in 5 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Aug 27, 2025. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 793,213,700 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.692%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
-111.23%
Trailing 12-Months
Asset Growth
-20.97%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―